Why the study?
Following certification of serotype 3 wild poliovirus eradication while serotype 1 continues to transmit, the optimal timing of serotype 3 oral poliovirus vaccine cessation remained an open question.
Does globally coordinated cessation of serotype 3 oral poliovirus vaccine (OPV3) before serotype 1 OPV reduce cases of vaccine-associated paralytic polio and circulating vaccine-derived polioviruses globally?
Comparison
Different options for coordinated cessation of OPV3 prior to COVID-19
Design
Integrated global modeling study
Authors
Loading...
Persistent serotype 1 transmission renders prior OPV cessation timelines obsolete; leaves open updated polio endgame strategies.
Does globally coordinated cessation of serotype 3 oral poliovirus vaccine (OPV3) before serotype 1 OPV reduce cases of vaccine-associated paralytic polio and circulating vaccine-derived polioviruses globally?
Early coordinated cessation of OPV3 could reduce vaccine-associated paralytic polio and the risk of circulating vaccine-derived polioviruses.
Kalkowska et al. (2020) studied this question.